Applications of bioluminescent research tools presented at a series of global seminars

MADISON, Wisconsin – (COMMERCIAL THREAD) – Life sciences and drug discovery researchers interested in bioluminescent tools will have the opportunity to hear from global thought leaders on the possibilities and applications of luciferase technologies during the next round of Discover Glo Virtual Seminars 2021. Hosted by Promega and held September 13-16, the series will advance understanding in important therapeutic areas such as targeted protein degradation and kinase biology.

Over the past three decades, tests and technologies using the natural phenomenon of bioluminescence have evolved from new research tools to foundational elements of the modern research toolbox. Innovation using bioluminescent approaches continues, further expanding the methods available and the scientific advancements made by researchers in life sciences and drug discovery.

Discover Glo 2021 will feature industry experts and scientists from Promega who will share updates on important research topics and recent technological advancements that can be applied to kinases, GPCRs, targeted protein degradation and to other drug targets and areas of research. In honor of the 30th anniversary of the first bioluminescent products launched by Promega, Bill Linton, President and CEO of Promega, will open the series with commentary on the past, present and future of bioluminescent technologies.

Discover the daily topics of Glo 2021:

  • Bioluminescence: Past, Present, Future (9/13)

  • Applications of CRISPR knock-in labeling for the study of the dynamics of endogenous proteins (9/14)

  • Understanding the engagement of the target Kinase in living cells (9/15)

  • Advances in targeted protein degradation (9/16)

Discover the Glo 2021 speakers:

  • Alessio Cuilli, Professor of Chemical and Structural Biology, University of Dundee

  • Susanne Müller-Knapp, Chief Operating Officer, SGC-Frankfurt, Chief Operating Officer of the Chemical Probes Portal

  • Kevin Pfleger, Director, Biomedical Innovation, The University of Western Australia and MTPConnect WA Life Sciences Innovation Hub

  • Takahide Matsushima, Assistant Professor, Tokyo Medical and Dental University

  • Benedict-Tilman Berger, Cellular Assays Team Leader, SGC Frankfurt

  • Pablo Marco-Moreno, Neurobiologist and PhD student, Biodonostia Health Research Institute

  • Thomas Machleidt, Group Director of Advanced Technologies, Promega

  • Danette Daniels, Senior Scientist, Promega

  • Matthew Robers, Principal Scientist, Promega

  • Christopher Eggers, Principal Scientist, Promega

  • Bill Linton, President and CEO, Promega

Discover Glo began in 2005 as an annual tour of European cities with presentations from Promega and local researchers. In 2020, the event was held virtually due to the COVID-19 pandemic. The seminars will be held virtually again in 2021, expanding access outside Europe to researchers from all over the world.

To see the full list of speakers and to register for the event, visit

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of more than 4,000 products supports a range of life science work in areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For more than 40 years, these tools and technologies have developed in their application and are today used by scientists and technicians in laboratories for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 distributors worldwide. For more information, visit

Source link

About Stephen Arrington

Check Also

Flint Group to Showcase Latest Innovations for Paper and Board at FEFCO Seminar – Covering Printing Inks, Coatings and Allied Industries

Packaging inks from Flint Group and Xeikon, another division of Flint Group, are attending the …

Leave a Reply

Your email address will not be published. Required fields are marked *